Inverness gets new glucose technology with LXN
This article was originally published in Clinica
Inverness Medical Technology is to acquire LXN, a privately owned US diabetes measurement company, which has the first and only US FDA approved glycated protein test, as well as offering a standard self-test blood glucose fingerstick test. The move has the potential to propel Inverness into direct competition with its exclusive distribution partner, Johnson & Johnson, with an enhanced glucose monitor. This technology is unavailable to J&J.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.